Gilead patent for its Sovaldi hepatitis C drug is rejected in Ukraine
Another reason to visit Egypt: Europe’s high drug prices
Non-profit group continues battle against Gilead patents
Medicines access group takes aim at Sovaldi patents
As more countries around the world reject unmerited patents for Sovaldi®, I-MAK Files Two New U.S. Patent Challenges on Gilead’s Hepatitis C Portfolio
Argentina Rejects Key Patent on Hepatitis C Drug
Patent ‘Trolls’ Recede as Threat to Innovation. Will Justices Change That?
There Is Only One Sure Way to Fix the Hepatitis C Epidemic
Seven Days
Nonprofit Group I-MAK Files IPR Petitions Seeking to Invalidate Hepatitis C Drug Patent